Genmab A/S Capital Increase In Genmab As A Result Of Employee Warrant Exercise

Date : 30/06/2020 @ 18:52
Source : UK Regulatory (RNS & others)

Genmab A/S Capital Increase In Genmab As A Result Of Employee Warrant Exercise

   Company Announcement 
   Copenhagen, Denmark; June 30, 2020 -- Genmab A/S (Nasdaq: GMAB) will 
increase its share capital by 66,487 shares as a consequence of the 
exercise of employee warrants. 
   The increase is effected without any preemption rights for the existing 
shareholders of the company or others. The shares are subscribed in cash 
at the following price per share of nominally DKK 1: 
   100 shares at DKK 31.75, 
   7,200 shares at DKK 40.41, 
   1,500 shares at DKK 55.85, 
   35,000 shares at DKK 66.60, 
   4,250 shares at DKK 225.90, 
   650 shares at DKK 231.50, 
   7,700 shares at DKK 337.40, 
   500 shares at DKK 636.50, 
   577 shares at DKK 815.50, 
   2,770 shares at DKK 939.50, 
   2,000 shares at DKK 1,136.00, 
   2,533 shares at DKK 1,145.00, 
   1,078 shares at DKK 1,233.00, 
   530 shares at DKK 1,408.00 and 
   99 shares at DKK 1,424. 
   Proceeds to the company are approximately DKK 17.2 million. The increase 
corresponds to approximately 0.10% of the company's share capital. 
   The new shares are ordinary shares without any special rights and are 
freely transferable negotiable instruments. The new shares give rights 
to dividends and other rights in relation to the company as of 
subscription, i.e. inter alia full rights to dividends for the financial 
year 2020. The new shares will be listed on Nasdaq Copenhagen after 
registration with the Danish Business Authority. The capital increase is 
expected to be finalized shortly. 
   Pursuant to section 32 of the Danish Capital Markets Act No 377 of April 
2, 2020, it is hereby announced, that the total nominal value of Genmab 
A/S' share capital after the capital increase is DKK 65,346,580 which is 
made up of 65,346,580 shares of a nominal value of DKK 1 each, 
corresponding to 65,346,580 votes. 
   About Genmab 
   Genmab is a publicly traded, international biotechnology company 
specializing in the creation and development of differentiated antibody 
therapeutics for the treatment of cancer. Founded in 1999, the company 
is the creator of three approved antibodies: DARZALEX(R) (daratumumab, 
under agreement with Janssen Biotech, Inc.) for the treatment of certain 
multiple myeloma indications in territories including the U.S., Europe 
and Japan, Arzerra(R) (ofatumumab, under agreement with Novartis AG), 
for the treatment of certain chronic lymphocytic leukemia indications in 
the U.S., Japan and certain other territories and TEPEZZA(TM) 
(teprotumumab, under agreement with Roche granting sublicense to Horizon 
Therapeutics plc) for the treatment of thyroid eye disease in the U.S. A 
subcutaneous formulation of daratumumab, known as DARZALEX FASPRO(TM) 
(daratumumab and hyaluronidase-fihj) in the U.S., has been approved in 
the U.S. and Europe for the treatment of adult patients with certain 
multiple myeloma indications. Daratumumab is in clinical development by 
Janssen for the treatment of additional multiple myeloma indications, 
other blood cancers and amyloidosis. A subcutaneous formulation of 
ofatumumab is in development by Novartis for the treatment of relapsing 
multiple sclerosis. Genmab also has a broad clinical and pre-clinical 
product pipeline. Genmab's technology base consists of validated and 
proprietary next generation antibody technologies - the DuoBody(R) 
platform for generation of bispecific antibodies, the HexaBody(R) 
platform, which creates effector function enhanced antibodies, the 
HexElect(R) platform, which combines two co-dependently acting HexaBody 
molecules to introduce selectivity while maximizing therapeutic potency 
and the DuoHexaBody(R) platform, which enhances the potential potency of 
bispecific antibodies through hexamerization. The company intends to 
leverage these technologies to create opportunities for full or 
co-ownership of future products. Genmab has alliances with top tier 
pharmaceutical and biotechnology companies. Genmab is headquartered in 
Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, 
New Jersey, U.S. and Tokyo, Japan. 
   Marisol Peron, Corporate Vice President, Communications & Investor 
   T: +1 609 524 0065; E: 
   For Investor Relations: 
   Andrew Carlsen, Senior Director, Investor Relations 
   T: +45 3377 9558; E: 
   This Company Announcement contains forward looking statements. The words 
"believe", "expect", "anticipate", "intend" and "plan" and similar 
expressions identify forward looking statements. Actual results or 
performance may differ materially from any future results or performance 
expressed or implied by such statements. The important factors that 
could cause our actual results or performance to differ materially 
include, among others, risks associated with pre-clinical and clinical 
development of products, uncertainties related to the outcome and 
conduct of clinical trials including unforeseen safety issues, 
uncertainties related to product manufacturing, the lack of market 
acceptance of our products, our inability to manage growth, the 
competitive environment in relation to our business area and markets, 
our inability to attract and retain suitably qualified personnel, the 
unenforceability or lack of protection of our patents and proprietary 
rights, our relationships with affiliated entities, changes and 
developments in technology which may render our products or technologies 
obsolete, and other factors. For a further discussion of these risks, 
please refer to the risk management sections in Genmab's most recent 
financial reports, which are available on and the risk factors included in Genmab's most recent 
Annual Report on Form 20-F and other filings with the U.S. Securities 
and Exchange Commission (SEC), which are available at Genmab does not undertake any obligation to update or 
revise forward looking statements in this Company Announcement nor to 
confirm such statements to reflect subsequent events or circumstances 
after the date made or in relation to actual results, unless required by 
   Genmab A/S and/or its subsidiaries own the following trademarks: 
Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination with the 
Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ; DuoBody in combination 
with the DuoBody logo(R) ; HexaBody(R) ; HexaBody in combination with 
the HexaBody logo(R) ; DuoHexaBody(R) ; HexElect(R) ; and UniBody(R) . 
Arzerra(R) is a trademark of Novartis AG or its affiliates. DARZALEX(R) 
and DARZALEX FASPRO(TM) are trademarks of Janssen Pharmaceutica NV. 
TEPEZZA(TM) is a trademark of Horizon Therapeutics plc. 
   Company Announcement no. 27 
   CVR no. 2102 3884 
   LEI Code 529900MTJPDPE4MHJ122 
   Genmab A/S 
   Kalvebod Brygge 43 
   1560 Copenhagen V 
   -- 300620_CA27_Warrant Exercise 

(END) Dow Jones Newswires

June 30, 2020 13:52 ET (17:52 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
ADVFN Advertorial
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200703 18:28:22